Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435866 | 0.90 | SLC6A3 (0.67) | SLC6A3HSD11B1SLC6A4SLC6A2 | |
| SCHEMBL16771203 | 0.86 | SLC6A4 (0.53) | SLC6A3HSD11B1SLC6A4SLC6A2 | |
| SCHEMBL14341371 | 0.86 | SLC6A3 (0.41) | SLC6A3HSD11B1SLC6A4SLC6A2 | |
| SCHEMBL11821978 | 0.85 | HSD11B1 (0.46) | SLC6A3HSD11B1SLC6A4SLC6A2PRKAB2 | |
| SCHEMBL6168782 | 0.83 | OPRM1 (0.50) | SLC6A3HSD11B1SLC6A4SLC6A2 | |
| SCHEMBL11920268 | 0.80 | SLC6A4 (0.41) | SLC6A3HSD11B1SLC6A4SLC6A2 | |
| SCHEMBL5484212 | 0.80 | SLC6A4 (0.41) | SLC6A3HSD11B1SLC6A4SLC6A2 | |
| SCHEMBL5484210 | 0.80 | SLC6A4 (0.41) | SLC6A3HSD11B1SLC6A4SLC6A2 | |
| SCHEMBL2513034 | 0.79 | SLC6A4 (0.48) | SLC6A3HSD11B1SLC6A4SLC6A2 | |
| SCHEMBL2425390 | 0.79 | HSD11B1 (0.49) | SLC6A3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025015268-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2021071843-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10221156-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20180162831-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-14 | — | — | US | disclosed |
| CN-107835808-A | The acetic acid derivatives of pyridine 3 of the inhibitor replicated as human immunodeficiency virus | VIIV保健英国第五有限公司 | 2018-03-23 | — | — | CN | disclosed |
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
| EP-0900218-B1 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-0900218-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6117883-A | Heterocyclic compounds | ELI LILLY AND COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0900218-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040044-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| EP-0094085-B1 | ETHER COMPOUNDS, THEIR PRODUCTION AND AN INSECTICIDAL AND/OR ACARICIDAL COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-01-02 | — | — | EP | disclosed |
| US-4562213-A | Certain phenoxy-benzyloxy ether derivatives and an insecticidal and/or acaricidal composition containing the same and methods of use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-12-31 | — | — | US | disclosed |
| EP-0094085-A1 | Ether compounds, their production and an insecticidal and/or acaricidal composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162831-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DUT | SLC6A3 3469/4885HSD11B1 1683/4885SLC6A4 3671/4885 |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | GRM2, GRIK2, GRIA2 | SLC6A3 508/4885HSD11B1 3905/4885SLC6A4 906/4885 |
| US-10221156-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | TYMP, TYMS, DUT | SLC6A3 3469/4885HSD11B1 1683/4885SLC6A4 3671/4885 |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | SLC6A3 2326/4885HSD11B1 3474/4885SLC6A4 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.